With new CEO, Invitae lays off more than 1,000 employees, slims international footprint Biogen CEO Michel Vounatsos points to inherent risk in neuroscience as 3 programs cut Merck's Keytruda posts rare flop in head and neck cancer trial Dobbs decision 'opened the door for complete and utter chaos,' physicians and legal experts tell Congress Abbott holds onto billion-dollar COVID test sales a little longer, pushing decline predictions to this fall Novartis shelves a PD-1 bid in non-small cell lung cancer after FDA feedback Adial at a clinical fork in the road after flunking phase 3 trial for its alcohol addiction med Senate Democrats taking first action to advance deal on ACA subsidies, drug price reform AbbVie scopes out $60M upfront investment in glaucoma devicemaker, plus $475M buyout option An abundance of CAR-Ts: $37B cell therapy cancer market can't support 'congested' pipeline, report says Takeda weaves F-star tech into patchwork of cancer capabilities, landing license for bispecific program Elevance Health plans to take myNEXUS post-acute care program nationwide Equipped with fresh $100M, CAMP4 heads up trail to the clinic, hoping partners will soon tag along Featured Story | By Andrea Park Genetic testing company Invitae will lay off more than 1,000 employees as part of a year-long restructuring plan that’s expected to ultimately save the company hundreds of millions of dollars annually. read more |
| |
|---|
|
Top Stories By Annalee Armstrong In a sign of just how tough neuroscience is, Biogen is cutting a clutch of programs from its Alzheimer’s disease, amyotrophic lateral sclerosis and schizophrenia pipelines. read more By Fraiser Kansteiner Alongside chemoradiation therapy, Merck’s PD-1 inhibitor Keytruda failed to meet its primary endpoint in a late-stage trial for unresected locally advanced head and neck squamous cell carcinoma. While the drug did chart improvements in event-free survival, or the time a patient remains free of complications, the results weren’t statistically significant. read more By Dave Muoio The majority of clinical and legal witnesses testifying to lawmakers Tuesday outlined dangerous restrictions to reproductive and other care that have become more frequent amid an uncertain legal environment. read more By Conor Hale It appears that when it comes to COVID-19 test sales, the reports of their death have been greatly exaggerated. read more By Zoey Becker Shortly after the FDA delayed a tislelizumab decision in previously treated esophageal squamous cell carcinoma, Novartis is scrapping the drug's submission as a monotherapy for non-small cell lung cancer. read more By Max Bayer Adial flunked a phase 3 trial for its alcohol abuse treatment but says it accrued enough encouraging data that it will march to regulators anyway. The feedback will guide future development and partnership plans. read more By Robert King Democratic Senate leadership confirmed they are moving forward with a narrow spending package that would extend enhanced ACA subsidies for two years and give Medicare the power to negotiate for lower drug prices. read more By Andrea Park AbbVie has set its sights on a new medical device partnership to expand the scope of its existing eye care portfolio. read more By Fraiser Kansteiner There are more than 800 cell therapy prospects currently in the hopper for just five major blood cancers, GlobalData reports. If those therapies all pass muster at the FDA, the commercial market for cell therapies in oncology, expected to exceed $37 billion by 2028, won't be able to keep up. read more By Nick Paul Taylor Takeda has added another piece to the patchwork of bispecific antibody capabilities it's sewn together over the past 18 months, tapping F-star Therapeutics to support an immuno-oncology program. read more By Paige Minemyer Elevance Health, formerly Anthem, boosted its guidance on Wednesday even as its quarterly profit dipped year over year. read more By Max Bayer A year after raising $45 million, CAMP4 is back for more, tacking on $100 million in a series B round. The funds will provide further financial cushion as the company sets its sights on the clinic in 2023. read more Resources Sponsored by: NetApp Could cloud be the cure for your EHR headaches? See our infographic on how moving to the cloud can slash financial and administrative burdens. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 